covid-19 vaccine, mrna

Trade name: Comirnaty

Vaccineapproved

Approved

Aug 23, 2021

Clinical trial activity

1 trials · 3 clinical orgs · 1 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started May 31, 2025 (NCT06821126)

Timeline

2020s

  1. Aug 23, 2021

    Biontech — Earliest FDA Approval

  2. Aug 23, 2021

    Biontech — NDA Secondary Org

  3. Aug 23, 2021

    Biontech — NDA Organization

  4. Jan 1, 2025

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • SARS-CoV-2Immunity, active

    SARS-CoV-2 immunity, active

Approval history

  • approvedAug 23, 2021

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06821126Phase 1/Phase 2 (Phase 2)May 31, 2025Government of France, University Hospital, Tours, University of Paris
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of FranceGovernment1112025
University Hospital, ToursAcademic/Hospital1012025
University of ParisAcademic/Hospital1012025
3 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
BiontechFor profitNDA2Aug 23, 2021
BiontechFor profitNDAAug 23, 2021